Zevra Therapeutics, Inc. (ZVRA)
12.40
-0.14
(-1.12%)
USD |
NASDAQ |
Sep 04, 16:00
12.39
-0.01
(-0.08%)
After-Hours: 20:00
Zevra Therapeutics Research and Development Expense (Quarterly) : 4.486M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.486M |
| March 31, 2026 | 4.34M |
| December 31, 2025 | 2.574M |
| September 30, 2025 | 3.432M |
| June 30, 2025 | 3.433M |
| March 31, 2025 | 3.258M |
| December 31, 2024 | 6.704M |
| September 30, 2024 | 9.328M |
| June 30, 2024 | 8.959M |
| March 31, 2024 | 10.72M |
| December 31, 2023 | 10.44M |
| September 30, 2023 | 12.24M |
| June 30, 2023 | 7.355M |
| March 31, 2023 | 8.576M |
| December 31, 2022 | 6.241M |
| September 30, 2022 | 4.987M |
| June 30, 2022 | 4.614M |
| March 31, 2022 | 3.017M |
| December 31, 2021 | 2.745M |
| September 30, 2021 | 2.174M |
| June 30, 2021 | 2.784M |
| March 31, 2021 | 2.201M |
| December 31, 2020 | 2.988M |
| September 30, 2020 | 1.709M |
| Date | Value |
|---|---|
| June 30, 2020 | 1.954M |
| March 31, 2020 | 2.126M |
| December 31, 2019 | 2.39M |
| September 30, 2019 | 3.54M |
| June 30, 2019 | 4.803M |
| March 31, 2019 | 8.531M |
| December 31, 2018 | 6.304M |
| September 30, 2018 | 13.33M |
| June 30, 2018 | 10.49M |
| March 31, 2018 | 11.64M |
| December 31, 2017 | 5.536M |
| September 30, 2017 | 6.293M |
| June 30, 2017 | 4.65M |
| March 31, 2017 | 4.114M |
| December 31, 2016 | 7.973M |
| September 30, 2016 | 4.287M |
| June 30, 2016 | 4.988M |
| March 31, 2016 | 3.234M |
| December 31, 2015 | 4.716M |
| September 30, 2015 | 4.328M |
| June 30, 2015 | 2.768M |
| March 31, 2015 | 2.119M |
| December 31, 2014 | 5.911M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Innoviva, Inc. | 5.19M |
| Collegium Pharmaceutical, Inc. | -- |
| Johnson & Johnson | 3.603B |
| Ligand Pharmaceuticals, Inc. | 14.67M |
| Harrow, Inc. | 8.072M |